Michelle S. Ginsberg

Michelle S. Ginsberg

Auto-generated profile, based on publicly available information

Michelle S. Ginsberg

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Radiology
Verified
Journal Article
Closed access
RPRocio Perez-Johnston
Rocio Perez-Johnston
JAJose A. Araujo-Filho
Jose A. Araujo-Filho
JCJames G. Connolly
James G. Connolly
RCRaul Caso
Raul Caso
KWKarissa Whiting
Karissa Whiting
DJDavid Jones
David Jones
CT-based radiomic features were significantly associated with prognostic histopathologic features, specific genomic alterations, and recurrence-specific survival in patients with clinical stage I l... Background A preoperative predictive model is needed that can be used to identify patients with lung adenocarcinoma (LUAD) who have a higher risk of recurrence or metastasis. Purpose To investigate...

24 May 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NCNoura J Choudhury
Noura J Choudhury
JLJessica Lavery
Jessica Lavery
SBSamantha Brown
Samantha Brown
IBIno de Bruijn
Ino de Bruijn
JJJustin Jee
Justin Jee
GRGregory J Riely
Gregory J Riely
Purpose: We describe the clinical and genomic landscape of the non–small cell lung cancer (NSCLC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Experimental Design: A total of 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions participating in AACR GENIE were randomly chosen for curation using the PRISSMM data model. Progression-free survival (PFS) and overall survival (OS) were estimated for patients treated with standard therapies. Results: In this cohort, 44% of tumors harbored a targetable oncogenic alteration, with EGFR (20%), KRAS G12C (13%), and oncogenic fusions (ALK, RET, and ROS1; 5%) as the most frequent. Median OS (mOS) on first-line platinum-based therapy without immunotherapy was 17.4 months [95% confidence interval (CI), 14.9–19.5 months]. For second-line therapies, mOS was 9.2 months (95% CI, 7.5–11.3 months) for immune checkpoint inhibitors (ICI) and 6.4 months (95% CI, 5.1–8.1 months) for docetaxel ± ramucirumab. In a subset of patients treated with ICI in the second-line or later setting, median RECIST PFS (2.5 months; 95% CI, 2.2–2.8) and median real-world PFS based on imaging reports (2.2 months; 95% CI, 1.7–2.6) were similar. In exploratory analysis of the impact of tumor mutational burden (TMB) on survival on ICI treatment in the second-line or higher setting, TMB z-score harmonized across gene panels was associated with improved OS (univariable HR, 0.85; P = 0.03; n = 247 patients). Conclusions: The GENIE BPC cohort provides comprehensive clinicogenomic data for patients with NSCLC, which can improve understanding of real-world patient outcomes.

28 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
NCNoura J. Choudhury
Noura J. Choudhury
WLW. Victoria Lai
W. Victoria Lai
AMAlex Makhnin
Alex Makhnin
GHGlenn Heller
Glenn Heller
JEJuliana Eng
Juliana Eng
CRCharles M. Rudin
Charles M. Rudin
Purpose: Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted. Patients and Methods: This phase I/II trial investigated valemetostat, an EZH1/2 inhibitor, with fixed-dose irinotecan in patients with recurrent SCLC. Phase I primary objectives were to assess safety, tolerability, and a recommended phase II dose (RP2D). The phase II primary objective was overall response rate (ORR), with secondary objectives of determining duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Correlative analyses included immunohistochemistry of pretreatment and on-treatment tumor biopsies and pharmacokinetics analysis. Results: Twenty-two patients were enrolled (phase I, n = 12; phase II, n = 10); one withdrew consent prior to treatment. Three dose-limiting toxicities (DLT) in dose-escalation resulted in valemetostat 100 mg orally daily selected as RP2D. Among 21 evaluable patients, the most frequent (≥20%) treatment-related adverse events were diarrhea, fatigue, nausea, and rash; three patients discontinued treatment for toxicity. Three of the first 10 patients in phase II experienced DLTs triggering a stopping rule. The ORR was 4/19 or 21% [95% confidence interval (CI), 6%–46%]. The median DoR, PFS, and OS were 4.6 months, 2.2 months (95% CI, 1.3–7.6 months), and 6.6 months (95% CI, 4.3 to not reached), respectively. SLFN11/EZH2 expression and SCLC subtyping markers did not correlate with response, but MHC-I expression did increase with treatment. Two responders demonstrated subtype switching on treatment. Conclusions: Combination valemetostat and irinotecan was not tolerated but demonstrated efficacy in recurrent SCLC. Valemetostat, combined with agents without overlapping toxicity, warrants further investigation in SCLC.

21 February 2023 in Lung Cancer
Verified
Journal Article
Closed access
MMMaria Mayoral
Maria Mayoral
APAndrew M. Pagano
Andrew M. Pagano
JAJose Arimateia Batista Araujo-Filho
Jose Arimateia Batista Araujo-Filho
JZJunting Zheng
Junting Zheng
RPRocio Perez-Johnston
Rocio Perez-Johnston
MGMichelle S. Ginsberg
Michelle S. Ginsberg

1 December 2010 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRobert Motzer
Robert Motzer
GHGary R. Hudes
Gary R. Hudes
MGMichelle S. Ginsberg
Michelle S. Ginsberg
MBMichael S. Baum
Michael S. Baum
CHCharles S. Harmon
Charles S. Harmon
BRBruce G. Redman
Bruce G. Redman
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors with proven clinical benefit in patients with metastatic renal cell carcinoma (RCC). This phase I/II study investigated sunitinib in combination with an epidermal growth factor receptor inhibitor, gefitinib, in patients with metastatic RCC. In phase I, patients received sunitinib 37.5 or 50 mg in 6-week cycles (4 weeks on treatment, 2 off) plus gefitinib 250 mg, both once daily, to determine the sunitinib maximum tolerated dose (MTD). Pharmacokinetics was assessed for both drugs. In phase II, patients received sunitinib MTD plus gefitinib to evaluate the safety and antitumor activity of this combination. Forty-two patients were enrolled: 11 in phase I, and 31 in phase II. In phase I, 2 dose-limiting toxicities were observed with sunitinib 50 mg (grade 2 left ventricular ejection fraction decline and grade 3 fatigue), and 37.5 mg was declared the MTD. Thirteen patients treated at the MTD achieved a partial response (objective response rate: 37%; 95% confidence interval, 22-55) and 12 (34%) had stable disease. Median progression-free survival was 11 months (95% confidence interval, 6-17). The most commonly reported grade 3/4 treatment-related adverse event was diarrhea (14%), the only grade 3/4 adverse event to occur in >2 patients. Pharmacokinetic analyses did not indicate any drug-drug interactions. In metastatic RCC, sunitinib plus gefitinib demonstrated comparable efficacy to sunitinib monotherapy with an acceptable safety profile. Dosing, pharmacokinetic profile, and safety support study of sunitinib plus an epidermal growth factor receptor inhibitor in other tumor types.

1 June 1997 in American Journal of Roentgenology
Verified
Journal Article
Closed access
LSL H Schwartz
L H Schwartz
DPD M Panicek
D M Panicek
MDM V Doyle
M V Doyle
MGM S Ginsberg
M S Ginsberg
SHS K Herman
S K Herman
MBM Burt
M Burt
This study was performed to compare two proposed algorithms used when evaluating an adrenal mass discovered during staging evaluation of a patient with a known malignancy. Such evaluation was meant to lead to determination of the relative charges associated with each algorithm.Fifty-four patients with known malignancies who required evaluation of an adrenal mass underwent both chemical shift imaging (CSI) and CT-guided for CSI. The hospital charges incurred for each procedure and any associated complications were normalized using national relative-value scale charges and conversion factors. A decision analysis was performed to compare the relative charges that would have been incurred if adrenal MR imaging had been performed in all patients, followed by CT-guided biopsy only in those patients with MR findings not diagnostic of adrenocortical adenoma, and the relative charges incurred if only CT-guided adrenal biopsy had been performed in every patient.Twenty-three (43%) of 54 adrenal masses were shown to ...